- Wegovy (semaglutide 2.4mg) is the first GLP-1 receptor agonist FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
- It's the same active ingredient as Ozempic (semaglutide) but at a higher maximum dose (2.4mg vs 2.0mg) and with a weight-loss indication.
- Clinical trials showed an average weight loss of 14.9% of body weight over 68 weeks — roughly 33 lbs for someone starting at 220 lbs.
- The dose escalation takes 16-20 weeks to reach the full 2.4mg dose. This gradual ramp-up is essential for tolerability.
- Tracking your injections, weight, side effects, and meals with a companion app helps maximize results and gives your doctor better data to work with.
Wegovy is the brand name for semaglutide 2.4mg, a once-weekly injectable medication manufactured by Novo Nordisk. The FDA approved Wegovy in June 2021 specifically for chronic weight management in adults with a BMI of 30+ (obesity) or 27+ (overweight) with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol.
Wegovy and Ozempic contain the same active ingredient — semaglutide — and work through the same mechanism. The key differences are the approved indication (weight loss vs. diabetes), the maximum dose (2.4mg vs. 2.0mg), and the dose escalation schedule. If your doctor has prescribed one over the other, it's typically based on your insurance coverage, supply availability, and primary treatment goal.
How Does Wegovy Work?
Semaglutide mimics GLP-1, a hormone your gut naturally produces after eating. It acts on three fronts:
- Appetite suppression. Semaglutide activates GLP-1 receptors in the hypothalamus, reducing hunger signals and increasing feelings of fullness. Patients consistently describe a quieting of "food noise" — the persistent mental focus on food that makes weight management exhausting.
- Delayed gastric emptying. Food stays in the stomach longer, so you feel satisfied for hours after eating. This is a major factor in naturally reducing portion sizes without conscious restriction.
- Improved metabolic signaling. Beyond appetite, semaglutide improves insulin sensitivity and blood sugar regulation, which can reduce cravings and stabilize energy throughout the day.
Because semaglutide has a half-life of approximately 7 days, it's injected once weekly. Drug levels build gradually over 4-5 weeks at each dose, which is why the escalation schedule exists — it gives your body time to adapt.
Wegovy Dose Escalation Schedule
Wegovy's dose escalation is longer than Ozempic's because the target dose is higher. The FDA-approved schedule takes 16-20 weeks to reach the maintenance dose:
| Month | Dose | What to Expect |
|---|---|---|
| Month 1 (Weeks 1-4) | 0.25mg | Adjustment phase. Mild appetite changes, possible light nausea. Not yet a therapeutic dose. |
| Month 2 (Weeks 5-8) | 0.5mg | Appetite reduction becomes noticeable. Weight loss typically starts. Nausea may return briefly. |
| Month 3 (Weeks 9-12) | 1.0mg | Significant appetite suppression for most patients. Consistent weight loss. GI side effects usually improving. |
| Month 4 (Weeks 13-16) | 1.7mg | Approaching full strength. Appetite effects are strong. Some patients experience renewed nausea. |
| Month 5+ (Week 17+) | 2.4mg | Maintenance dose. Maximum appetite suppression and weight-loss effect. Steady state reached in 4-5 weeks. |
What Do the Clinical Trials Show?
Wegovy's approval was based on the STEP clinical trial program — one of the largest weight-management trial series ever conducted. Key results from the STEP 1 trial (published in the New England Journal of Medicine):
- Average weight loss: 14.9% of body weight over 68 weeks (vs. 2.4% for placebo)
- Clinically meaningful loss: 86% of participants lost at least 5% of their body weight; 69% lost at least 10%; 50% lost at least 15%
- Improvements beyond weight: Reductions in waist circumference, blood pressure, blood sugar (A1C), triglycerides, and C-reactive protein (a marker of inflammation)
In 2023, the SELECT trial demonstrated that semaglutide also reduces the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in overweight or obese adults with established cardiovascular disease. This was a landmark finding that expanded the medical rationale for weight-loss treatment.
Common Side Effects
Wegovy's side effects are similar to Ozempic's because they share the same active ingredient. The most common are gastrointestinal:
- Nausea (44% of patients in trials) — Typically worst in the first 1-2 weeks at each new dose level. Eating smaller, more frequent meals and avoiding high-fat foods helps significantly. Most patients find it manageable and improving over time.
- Diarrhea (30%) — Usually mild and temporary during dose escalation.
- Vomiting (24%) — More common at higher doses. If persistent, your doctor may slow the dose escalation.
- Constipation (24%) — Staying hydrated and eating fiber-rich foods helps. A fiber supplement can be useful during the adjustment period.
- Abdominal pain (20%) — Typically mild. Often related to eating too quickly or too much at once while the medication is slowing digestion.
Most GI side effects improve within 2-4 weeks at each dose level. For a week-by-week guide on what to expect, see our article on GLP-1 side effects in the first month.
Wegovy vs Ozempic: What's the Difference?
Both medications contain semaglutide. The practical differences:
- Approved use: Wegovy is FDA-approved for weight management. Ozempic is FDA-approved for type 2 diabetes (used off-label for weight loss).
- Maximum dose: Wegovy goes up to 2.4mg. Ozempic's max is 2.0mg.
- Insurance: Coverage depends on your plan. Some insurers cover Wegovy for weight loss but not Ozempic (and vice versa). Many patients end up on whichever one their insurance covers.
- Supply: Both have experienced shortages since 2022. Availability varies by pharmacy and region.
From a tracking and behavioral standpoint, both medications work the same way. Whether you're on Wegovy or Ozempic, the behavioral strategies that complement treatment are identical: track your injections, stay aware of your meals, monitor your weight trend, and reflect daily.
How to Track Your Wegovy Treatment
The 16-20 week dose escalation alone makes tracking essential. You're changing doses every month, and each change brings new adjustments. Without a record, it's hard to remember what happened at which dose — and even harder to communicate effectively with your doctor.
What to track:
- Injection log. Date, time, dose, and injection site for every shot. Rotating between abdomen, thigh, and upper arm prevents injection site reactions.
- Side effects by dose level. Knowing that nausea was manageable at 1.0mg but intolerable at 1.7mg gives your doctor actionable information for adjusting your treatment.
- Weight trend. Weekly or daily — just be consistent. Look at the 4-8 week trend, not individual days.
- Meal check-ins. Even a simple supportive/unsupportive assessment builds awareness of your eating patterns as they change with each dose increase. You don't need to count calories — learn more about the meal awareness approach.
A GLP-1 companion app like MyWhy handles all of this in one place — injection tracking, drug-level visualization, meal check-ins, weight trends, and daily reflections. All free. See how it compares in our best free GLP-1 tracking apps guide.